A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
- Zhang, Xiao
- Zhao, Bingchun
- Ding, Mingmei
- Song, Shuo
- Kang, Yinfeng
- Yu, Yang
- Xu, Miao
- Xiang, Tong
- Gao, Ling
- Feng, Qisheng
- Zhao, Qinjian
- Zeng, Mu-Sheng
- Krummenacher, Claude
- Zeng, Yi-Xin
Publication date
January 2020
DOI Publisher
Ivyspring International Publisher Language
EnglishAbstract
Epstein-Barr virus (EBV) is the causative pathogen for infectious mononucleosis and many kinds of malignancies including several lymphomas such as Hodgkin\u27s lymphoma, Burkitt\u27s lymphoma and NK/T cell lymphoma as well as carcinomas such as nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma (EBV-GC). However, to date no available prophylactic vaccine was launched to the market for clinical use
Add to ORKG